Price$59.97+5.90 (+10.91%)
2026-03-042026-06-05
News · 26 weeks64+10%
2025-12-142026-06-07
Mix3990d
- Insider12(31%)
- Other12(31%)
- SEC Filings8(21%)
- Analyst4(10%)
- Earnings2(5%)
- Leadership1(3%)
Latest news
25 items- INSIDERChief Growth Officer Partridge Andrew John sold $91,070 worth of shares (1,491 units at $61.08), decreasing direct ownership by 0.90% to 163,738 units (SEC Form 4) (withholding obligation)4 - GRAIL, Inc. (0001699031) (Issuer)
- ANALYSTGoldman initiated coverage on GRAIL with a new price targetGoldman initiated coverage of GRAIL with a rating of Neutral and set a new price target of $60.00
- INSIDERChief Executive Officer Ofman Joshua J. was granted 31,055 shares, increasing direct ownership by 8% to 402,271 units (SEC Form 4)4 - GRAIL, Inc. (0001699031) (Issuer)
- INSIDERNew insider Partridge Andrew John claimed ownership of 165,229 shares (SEC Form 3)3 - GRAIL, Inc. (0001699031) (Issuer)
- ANALYSTWolfe Research resumed coverage on GRAILWolfe Research resumed coverage of GRAIL with a rating of Peer Perform
- SECGRAIL Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits8-K - GRAIL, Inc. (0001699031) (Filer)
- PRGRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual MeetingThe Galleri Multi-Cancer Early Detection (MCED) Test Increased Cancer Detection 6.5 Fold When Added to Recommended Screenings for Breast, Colorectal, Cervical and Lung Cancer71% of the New Cancers Detected by the Galleri Test Were in Stages I-IIIMENLO PARK, Calif., May 31, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that positive performance and safety results from the analysis of the full 35,878 cohort of its registrational PATHFINDER 2 study are being presented during an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting[1]. Th
- PRGRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual MeetingNo Reduction Observed in Combined Primary Endpoint of Stage III/IV Cancers in Aggregate; However, Decreases Observed Beyond the Prevalent Screening Round Annual Galleri® Blood Test Reduced Stage IV Diagnoses of 12 Prespecified Cancers by 22% and 26% in the Second and Third Screening Rounds, RespectivelyGalleri Increased Cancer Detection Rate by Four-Fold When Added to Standard of Care Screening and Reduced Cancer Diagnosis Through Emergency Presentation by 25%Annual Testing With Galleri Increased Stage I-II Cancer Diagnoses by 16% When Added to Standard of CareGRAIL to Host Analyst Call From 2026 ASCO Annual Meeting MENLO PARK, Calif., May 30, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL),
- PRGRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)MENLO PARK, Calif., May 27, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 34,350 shares of GRAIL's common stock to 56 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL. The employment inducement awards were granted under GRAIL's Inducement Equity Incentive Plan and related form of restricted stock award agreement in accordance with Nasdaq Listing Rule 5635(c)(4).
- PRGRAIL to Present at the Goldman Sachs 47th Annual Global Healthcare ConferenceMENLO PARK, Calif., May 26, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, FL on Tuesday, June 9 at 11:20 a.m. ET. Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event.About GRAILGRAIL is a healthcare company whose missi
- PRGRAIL to Present at the 2026 Jefferies Global Healthcare ConferenceMENLO PARK, Calif., May 21, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the 2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3 at 7:35 a.m. ET. Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event.About GRAILGRAIL is a healthcare company whose mission is to de
- SECAmendment: SEC Form SCHEDULE 13G/A filed by GRAIL Inc.SCHEDULE 13G/A - GRAIL, Inc. (0001699031) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by GRAIL Inc.SCHEDULE 13G/A - GRAIL, Inc. (0001699031) (Subject)
- SECSEC Form 10-Q filed by GRAIL Inc.10-Q - GRAIL, Inc. (0001699031) (Filer)
- SECGRAIL Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - GRAIL, Inc. (0001699031) (Filer)
- PRGRAIL Reports First Quarter 2026 Financial ResultsQ1 Galleri® Revenue Grew 37% Year-Over-Year to $39.8 Million, and Test Volume Increased 50% to More Than 56,000Announced Plans to Integrate the Galleri Test Into Epic Electronic Health Record Platform to Expand Access NationwideNew Data From the NHS-Galleri Trial and PATHFINDER 2 Study to be Presented at 2026 American Society of Clinical Oncology (ASCO) Annual MeetingMENLO PARK, Calif., May 5, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the first quarter of 2026.
- PRGRAIL to Present at the BofA Securities 2026 Health Care ConferenceMENLO PARK, Calif., April 30, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the BofA Securities 2026 Health Care Conference in Las Vegas on Tuesday, May 12 at 8:40 a.m. PT. Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event.About GRAILGRAIL is a healthcare company whose mission is to d
- SECSEC Form DEFA14A filed by GRAIL Inc.DEFA14A - GRAIL, Inc. (0001699031) (Filer)
- SECSEC Form DEF 14A filed by GRAIL Inc.DEF 14A - GRAIL, Inc. (0001699031) (Filer)
- PRGRAIL to Announce First Quarter 2026 Financial ResultsMENLO PARK, Calif., April 22, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the first quarter 2026 following the close of market on Tuesday, May 5, 2026. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss results and business progress. First Quarter 2026 Webcast and Conference Call DetailsA link to the live webcast and recorded replay will be available at the investor
- PRGRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at 2026 ASCO Annual MeetingDetailed NHS-Galleri Trial Results Will be Presented as a Late-Breaking Abstract in an Oral Presentation Final PATHFINDER 2 Study Results Will be Presented as a Late-Breaking Abstract in an Oral Presentation More than 174,000 Participants Enrolled Across Both Studies, Demonstrating the Scientific Rigor of Galleri® Clinical Development ProgramMENLO PARK, Calif., April 21, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, will present additional data from both the NHS-Galleri trial and the PATHFINDER 2 study further evaluating the Galleri® multi-cancer early detection (MCED) test at the 2026 American Society of Cl
- INSIDERSEC Form 4 filed by Summe Gregory L4 - GRAIL, Inc. (0001699031) (Issuer)
- INSIDERSEC Form 4 filed by Chase William J4 - GRAIL, Inc. (0001699031) (Issuer)
- INSIDERSEC Form 4 filed by Mizell Steven4 - GRAIL, Inc. (0001699031) (Issuer)
- ANALYSTMizuho initiated coverage on GRAIL with a new price targetMizuho initiated coverage of GRAIL with a rating of Neutral and set a new price target of $58.00
GRAL FAQ
5 questionsWhere does GRAL stock trade?
GRAIL Inc. (GRAL) is listed on NASDAQ.What sector and industry is GRAL in?
GRAIL Inc. operates in the Health Care sector, Medical Specialities industry.What are analysts saying about GRAL?
GRAIL Inc. has had 8 recent analyst actions on file. The most recent action was from Goldman: Neutral on 2026-06-05.What companies are similar to GRAL?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), HUM (Humana Inc.). Compare GRAL side-by-side with any of them on Quantisnow.How can I track GRAL on Quantisnow?
Quantisnow aggregates GRAIL Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GRAL to receive live email and push alerts on every new disclosure.